Table 1.
Patients clinical characteristics before treatment.
| Age at initiation of treatment (median ± S.D.) (n = 33)* | 59 ± 10.77 |
| Sex ( n = 33) | |
| Female | 14/33 (42%) |
| Male | 19/33 (58%) |
| Grade ( n = 33) | |
| Grade I-II | 30/33 (90.9%) |
| Grade III | 3/33 (9.1%) |
| Ann Arbor stage ( n = 33) | |
| I | 1/33 (3.1%) |
| II | 4/33 (12.1%) |
| III | 11/33 (33.3%) |
| IV | 17/33 (51.5%) |
| LDH elevated (n = 33) | 7/33 (21.2%) |
| Serum Beta-2 microglobuline elevated (n = 15) | 11/15 (73.3%) |
| Hemoglobin ≥ 12 g/dL (n = 33) | 31/33 (94%) |
| Longer diameter of the largest involved node > 6 cm (n = 24) | 13/24 (54.2%) |
| FLIPI score a ( n = 33) | |
| FLIPI ≤ 1 | 8/33 (24.2%) |
| FLIPI = 2 | 16/33 (48.5%) |
| FLIPI ≥ 3 | 9/33 (27.3%) |
*n = Total number of patients for which the clinical data were available.
aFollicular Lymphoma International Prognostic Index (FLIPI) is based on a combined score of five parameters that include age (>60 vs ≤60 years), stage (III-IV vs I-II), anemia (hemoglobin <12 vs ≥12 dg/L), number of involved node areas (>4 vs ≤4) and serum LDH (elevated vs normal). FLIPI scores ≤1, 2, ≥3 classify patients into three groups with 10-year overall OS rates of 71%, 51% and 36%, respectively51.